AstraZeneca to establish centers of excellence for severe asthma in India
NEW DELHI : AstraZeneca India today announced plans to launch five Centers of Excellence in New Delhi, Ahmedabad, Goa and Cochin to provide a systematic approach to standardized and unified treatment of patients with severe asthma.
The centers will serve as the hub for the treatment and management of severe asthma patients, and in turn will guide and support the developing severe asthma centers for a systematic and guideline-based approach to identify and treat severe asthma patients.
“The Centers of Excellence (COEs) for Severe Asthma, under guidelines established by the Global Initiative for Asthma (GINA), would focus on specialist and clinical assessment, diagnosis, patient counseling, biologic drug initiation and data management related to severe asthma . The management of severe asthma requires ongoing research, education, and patient support. Proper patient selection is critical to the application of biologics or advanced precision therapy for severe asthma,” the company said in a statement.
“We have invested heavily in developing ‘Beyond the Pill’ solutions to accelerate, improve and scale holistic respiratory care across the healthcare ecosystem. In India, severe asthma is largely controlled by oral glucocorticoids which have side effects such as osteoporosis, hypertension, ulcers, weight gain, etc. despite the availability of newer treatment options such as biologics which have been shown to improve patient outcomes. Our goal is to establish more such centers of excellence across the country and address complications by continuously monitoring patients, educating healthcare providers and improving respiratory health for all.” Dr. Anil Kukreja, Vice President Medical Affairs & Regulatory, AstraZeneca India in the story.
Catch all company news and updates on Live Mint. Download the Mint News app for daily market updates and live business news.